Azenta, Inc. has made a significant advancement in its gene synthesis capabilities by entering into a strategic partnership with Elegen Corp. and acquiring SynPlexity Inc. This move, announced on October 30, 2026, is expected to enhance Azenta's GENEWIZ business, positioning it for long-term growth in the biotechnology sector.

The agreements include a Technology, Equipment and License Agreement and a Master Services and Supply Agreement with Elegen, as well as a Stock Purchase Agreement for the acquisition of SynPlexity. These initiatives are designed to strengthen Azenta's offerings in gene synthesis and related services.

Background

Azenta, Inc. operates in the Special Industry Machinery sector (SIC 3559) and is listed on the Nasdaq under the ticker AZTA. The company specializes in providing life sciences solutions, including cold-chain sample management and multiomics services. Recent filings indicate that Azenta is focused on expanding its capabilities and market presence, particularly in the fields of drug development and clinical research.

What the Filing Says

According to the SEC filing (accession number 0001628280-26-068443), Azenta entered into the Elegen Agreements on October 28, 2026. The License Agreement grants Azenta an exclusive, royalty-free license to Elegen's proprietary technology for gene synthesis and cell-free cloning. This arrangement is expected to support the expansion of Azenta's GENEWIZ capabilities and production capacity.

The License Agreement has an initial term of five years and may be converted into a perpetual license for $25 million. The Supply Agreement will see Elegen providing proprietary consumables and services to Azenta. Overall, the capital deployment related to these agreements is anticipated to range from $32 million to $71 million.

Impact

This strategic move is poised to affect various stakeholders, including Azenta's customers, employees, and competitors in the biotechnology sector. The acquisition of SynPlexity, which specializes in DNA assembly technology, will enhance Azenta's capabilities in delivering high-throughput gene libraries for drug discovery and other applications.

What's Next

Details regarding future developments and the integration of these agreements will be provided in Azenta's upcoming earnings call for the fourth quarter of fiscal 2026. The company also plans to file the full agreements as exhibits to its Quarterly Report on Form 10-Q for the fiscal quarter ending December 31, 2026.